Flt3 ligand does not differentiate between Parkinsonian disorders.
Författare
Summary, in English
Differential diagnosis of parkinsonian disorders is challenging because of overlapping symptoms, especially during early stages of disease. No validated biomarkers are available for early and accurate diagnosis of multiple system atrophy and other parkinsonian disorders. It has been reported that flt3 ligand levels in cerebrospinal fluid could clearly differentiate patients with Parkinson's disease from patients with multiple system atrophy, with 99% sensitivity and 95% specificity.
Avdelning/ar
Publiceringsår
2014
Språk
Engelska
Sidor
1319-1322
Publikation/Tidskrift/Serie
Movement Disorders
Volym
29
Issue
10
Länkar
Dokumenttyp
Artikel i tidskrift
Förlag
John Wiley & Sons Inc.
Ämne
- Neurology
Status
Published
Forskningsgrupp
- Biomarkers in Brain Disease
- Clinical Memory Research
ISBN/ISSN/Övrigt
- ISSN: 0885-3185